{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-030896","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2026-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.012267+00:00","generated_at":"2026-05-14T22:32:21.055335+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Madrigal Q1 Rezdiffra net sales $311.3M (+127% YoY); pipeline expanded with siRNA deal","bullets":["Q1 2026 Rezdiffra net sales $311.3M, up 127% YoY from $137.3M; over 42,250 patients on therapy, 2.5x vs Q1 2025.","Licensed ARO-PNPLA3 from Arrowhead; clinical-stage siRNA targeting PNPLA3 mutation in MASH (≈30% of F2/F3 patients).","Net loss $94.4M ($3.25/share) vs $73.2M ($2.61) prior year; includes $54.3M one-time upfront BD expenses.","Cash $817.9M at Mar 31 (down from $988.6M Dec 31); MGL-2086 Phase 1 on track for Q2 2026.","Operating expenses $404.1M (incl $34M stock comp) vs $216.6M; SG&A up due to commercial investment."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-030896","json":"https://secwatch.observer/filing/0001628280-26-030896.json","markdown":"https://secwatch.observer/filing/0001628280-26-030896.md","text":"https://secwatch.observer/filing/0001628280-26-030896.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026030896/0001628280-26-030896-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026030896/mdgl-20260506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:32:21.055335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9bee9b06118c4645c007065b80677d6ff039fc46","claim":"MADRIGAL PHARMACEUTICALS, INC. reported the quarter ended March 31, 2026 results: revenue $311.3 million, net income ($94.4 million) or ($3.25) per share (basic and diluted), EPS ($3.25).","evidence_excerpt":"(EX-99.1) --- Madrigal Pharmaceuticals Reports First -Quarter 2026 Financial Results and Provides Corporate Updates • First-quarter 2026 Rezdiffra ® (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127% • As of March 31, 2026, more than 42,250 patients on Rezdiffra, up 2.5x from 1Q25, reflecting continued strong physician adoption and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026030896/0001628280-26-030896-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001104659-26-069227","ticker":"YSWY","company_name":"Yesway, Inc.","filed_at":"2026-06-02T11:35:47+00:00","headline":"Yesway reports Q1 net income $30.2M, Adjusted EBITDA $59.2M; introduces FY2026 outlook","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069227","json":"https://secwatch.observer/filing/0001104659-26-069227.json","markdown":"https://secwatch.observer/filing/0001104659-26-069227.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859836/000110465926069227/0001104659-26-069227-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859836/000110465926069227/tm2616553d1_8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"(EX-99.1) ---\n\nMadrigal Pharmaceuticals Reports First -Quarter 2026 Financial Results and Provides Corporate Updates • First-quarter 2026 Rezdiffra ® (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127% • As of March 31, 2026, more than 42,250 patients on Rezdiffra, up 2.5x from 1Q25, reflecting continued strong physician adoption and","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026030896/0001628280-26-030896-index.htm","comparable_excerpt":"On June 2, 2026, Yesway, Inc. issued a press release announcing its financial results for the three months ended March 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1859836/000110465926069227/0001104659-26-069227-index.htm"}},{"accession":"0001856437-26-000011","ticker":"VSCO","company_name":"Victoria's Secret & Co.","filed_at":"2026-06-02T11:01:54+00:00","headline":"Victoria's Secret Q1 sales up 15% to $1.56B, beats guidance; raises FY2026 outlook","event_type":"earnings","sec_items":["2.02","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001856437-26-000011","json":"https://secwatch.observer/filing/0001856437-26-000011.json","markdown":"https://secwatch.observer/filing/0001856437-26-000011.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856437/000185643726000011/0001856437-26-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856437/000185643726000011/vsco-20260602.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"(EX-99.1) ---\n\nMadrigal Pharmaceuticals Reports First -Quarter 2026 Financial Results and Provides Corporate Updates • First-quarter 2026 Rezdiffra ® (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127% • As of March 31, 2026, more than 42,250 patients on Rezdiffra, up 2.5x from 1Q25, reflecting continued strong physician adoption and","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026030896/0001628280-26-030896-index.htm","comparable_excerpt":"The Company reported net sales of $1.560 billion for the first quarter of 2026, an increase of 15% compared to net sales of $1.353 billion for the first quarter of 2025 and above the previously communicated guidance range of $1.490 billion to $1.525 billion. Total comparable sales for the first quarter of 2026 increased 13%. The Company reported operating income for the first quarter of 2026 of $76 million compared to operating income of $20 million in the first quarter of 2025. Net income was $48 million, or $0.56 per diluted share, for the first quarter of 2026 compared to net loss of $2 million, or $0.02 per diluted share, for the first quarter of 2025.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1856437/000185643726000011/0001856437-26-000011-index.htm"}},{"accession":"0000832988-26-000158","ticker":"SIG","company_name":"SIGNET JEWELERS LTD","filed_at":"2026-06-02T10:54:29+00:00","headline":"Signet Q1 sales $1.6B, SSS +1.8%; raises FY27 adjusted EPS guidance","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000832988-26-000158","json":"https://secwatch.observer/filing/0000832988-26-000158.json","markdown":"https://secwatch.observer/filing/0000832988-26-000158.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/832988/000083298826000158/0000832988-26-000158-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/832988/000083298826000158/sig-20260602.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"(EX-99.1) ---\n\nMadrigal Pharmaceuticals Reports First -Quarter 2026 Financial Results and Provides Corporate Updates • First-quarter 2026 Rezdiffra ® (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127% • As of March 31, 2026, more than 42,250 patients on Rezdiffra, up 2.5x from 1Q25, reflecting continued strong physician adoption and","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026030896/0001628280-26-030896-index.htm","comparable_excerpt":"On June 2, 2026, Signet Jewelers Limited (the \"Company\") issued a press release announcing results for the first quarter ended May 2, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/832988/000083298826000158/0000832988-26-000158-index.htm"}},{"accession":"0001104659-26-069198","ticker":"DG","company_name":"DOLLAR GENERAL CORP","filed_at":"2026-06-02T10:54:17+00:00","headline":"Dollar General Q1 EPS $2.00 beats expectations; raises FY2026 EPS guidance","event_type":"earnings","sec_items":["2.02","5.07","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069198","json":"https://secwatch.observer/filing/0001104659-26-069198.json","markdown":"https://secwatch.observer/filing/0001104659-26-069198.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/29534/000110465926069198/0001104659-26-069198-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/29534/000110465926069198/tm2616084d1_8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"(EX-99.1) ---\n\nMadrigal Pharmaceuticals Reports First -Quarter 2026 Financial Results and Provides Corporate Updates • First-quarter 2026 Rezdiffra ® (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127% • As of March 31, 2026, more than 42,250 patients on Rezdiffra, up 2.5x from 1Q25, reflecting continued strong physician adoption and","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026030896/0001628280-26-030896-index.htm","comparable_excerpt":"(NYSE: DG) today reported financial results for its first quarter (13 weeks) ended May 1, 2026. First Quarter Fiscal Year 2026\nHighlights · Net\n Sales Increased 3.4% to $10.8 Billion · Same-Store\n Sales Increased 2.0% · Operating\n Profit Increased 10.8% to $638.5 Million · Diluted\n Earnings Per Share (“EPS”) Increased 12.4% to $2.00 · Cash\n Flow From","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/29534/000110465926069198/0001104659-26-069198-index.htm"}},{"accession":"0001062993-26-002965","ticker":"HIVE","company_name":"HIVE Digital Technologies Ltd.","filed_at":"2026-06-02T10:23:19+00:00","headline":"HIVE FY2026 revenue $297.8M (+158% YoY); GAAP net loss $148.4M","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001062993-26-002965","json":"https://secwatch.observer/filing/0001062993-26-002965.json","markdown":"https://secwatch.observer/filing/0001062993-26-002965.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720424/000106299326002965/0001062993-26-002965-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720424/000106299326002965/form8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"(EX-99.1) ---\n\nMadrigal Pharmaceuticals Reports First -Quarter 2026 Financial Results and Provides Corporate Updates • First-quarter 2026 Rezdiffra ® (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127% • As of March 31, 2026, more than 42,250 patients on Rezdiffra, up 2.5x from 1Q25, reflecting continued strong physician adoption and","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026030896/0001628280-26-030896-index.htm","comparable_excerpt":"EXHIBIT 99.1 HIVE Digital Technologies Ltd.: Exhibit 99.1 - Filed by newsfilecorp.com Exhibit 99.1 HIVE DIGITAL TECHNOLOGIES LTD. HIVE Achieves FY2026 Total Revenue of $297.8 Million (+158% YoY), HIVE's BUZZ HPC Positioned for Growth This news release constitutes a \"designated news release\" for the purposes of the Company's prospectus supplement dated","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1720424/000106299326002965/0001062993-26-002965-index.htm"}},{"accession":"0000029644-26-000049","ticker":"DCI","company_name":"DONALDSON Co INC","filed_at":"2026-06-01T21:41:36+00:00","headline":"Donaldson Q3 FY2026 sales $995.1M (+5.8%), adj. EPS $1.06 (+7.1%)","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000029644-26-000049","json":"https://secwatch.observer/filing/0000029644-26-000049.json","markdown":"https://secwatch.observer/filing/0000029644-26-000049.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/29644/000002964426000049/0000029644-26-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/29644/000002964426000049/dci-20260602.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"(EX-99.1) ---\n\nMadrigal Pharmaceuticals Reports First -Quarter 2026 Financial Results and Provides Corporate Updates • First-quarter 2026 Rezdiffra ® (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127% • As of March 31, 2026, more than 42,250 patients on Rezdiffra, up 2.5x from 1Q25, reflecting continued strong physician adoption and","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026030896/0001628280-26-030896-index.htm","comparable_excerpt":"press release is furnished herewith as Exhibit 99.1. \n\n--- EX-99.1 (EX-99.1) ---\n\nDonaldson Reports Record Third Quarter Fiscal 2026 Sales and Earnings Third quarter sales of $995.1 million, up 5.8% Operating margin of 15.6%; All-time high adjusted operating margin of 16.6% GAAP EPS of $1.00; Adjusted EPS of $1.06, up 7.1% Closed margin-accretive Facet acquisition,","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/29644/000002964426000049/0000029644-26-000049-index.htm"}},{"accession":"0001104659-26-068983","ticker":"GMRS","company_name":"GMR Solutions Inc.","filed_at":"2026-06-01T20:45:55+00:00","headline":"GMR Solutions Q1 revenue $1.46B (+6.6% YoY), net income $106M (+180% YoY), guides FY26 rev $5.9-6.2B","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068983","json":"https://secwatch.observer/filing/0001104659-26-068983.json","markdown":"https://secwatch.observer/filing/0001104659-26-068983.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1898718/000110465926068983/0001104659-26-068983-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1898718/000110465926068983/gmrs-20260601x8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"(EX-99.1) ---\n\nMadrigal Pharmaceuticals Reports First -Quarter 2026 Financial Results and Provides Corporate Updates • First-quarter 2026 Rezdiffra ® (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127% • As of March 31, 2026, more than 42,250 patients on Rezdiffra, up 2.5x from 1Q25, reflecting continued strong physician adoption and","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026030896/0001628280-26-030896-index.htm","comparable_excerpt":"today announced financial results for the first quarter ended March 31, 2026, and full year 2026 financial guidance. First Quarter 2026 Financial Highlights ● Net revenue of $1,457.6 million, up 6.6% compared to $1,367.4 million in the first quarter of 2025 ● Net income of $106.3 million, up 179.7% compared to $38.0 million in the first quarter of 2025 ● Adjusted","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1898718/000110465926068983/0001104659-26-068983-index.htm"}},{"accession":"0001645590-26-000052","ticker":"HPE","company_name":"Hewlett Packard Enterprise Co","filed_at":"2026-06-01T20:09:22+00:00","headline":"HPE Q2 FY26: record revenue $10.7B (+40%), raises FY26 guidance, introduces FY27 framework","event_type":"earnings","sec_items":["1.01","2.02","5.02","7.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001645590-26-000052","json":"https://secwatch.observer/filing/0001645590-26-000052.json","markdown":"https://secwatch.observer/filing/0001645590-26-000052.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645590/000164559026000052/0001645590-26-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645590/000164559026000052/hpe-20260601.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"(EX-99.1) ---\n\nMadrigal Pharmaceuticals Reports First -Quarter 2026 Financial Results and Provides Corporate Updates • First-quarter 2026 Rezdiffra ® (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127% • As of March 31, 2026, more than 42,250 patients on Rezdiffra, up 2.5x from 1Q25, reflecting continued strong physician adoption and","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026030896/0001628280-26-030896-index.htm","comparable_excerpt":"gross margin, and non-GAAP diluted net EPS, as well as its highest-ever free cash flow generation for a second quarter. Second Quarter Fiscal 2026 Financial Results • Revenue : $10.7 billion, up 40% from the prior-year period • Gross margins : ◦ GAAP of 36.5%, up 810 basis points from the prior-year period and up 60 basis points sequentially ◦ Non-GAAP (1) of 36.9%,","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1645590/000164559026000052/0001645590-26-000052-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}